I
nsulin-like growth factor I (IGF I) can inhibit apoptosis of cardiac muscle cells. 1, 2 Apoptosis, ie, programmed cell death, is regulated by specific intracellular signaling pathways that ultimately induce cell self-destruction. 3 Although these pathways may differ in different tissues, 4 they usually converge, indicating common cell death mechanisms. 5 The details of these common mechanisms are yet known, but it is widely believed that caspase 3, a cysteine protease that belongs to a family of interleukin-1␤-converting enzymes, plays a critical role in this process. 6 Previous studies have shown that activation of caspase 3 leads to nucleosomal fragmentation of DNA, 6 a hallmark of apoptosis. The activities of caspase 3 can be regulated by the Bcl-2 protein family. Bcl-2 was the first member of the protein family to be identified; subsequently, several homologous proteins that share common BH domains were cloned. 5 Interestingly, some of these proteins, such as Bcl-2, block apoptosis, whereas others, such as Bax, promote cell death. Homodimers of Bcl-2 may stabilize the mitochondrial membrane and prevent the activation of downstream apoptotic signaling. 5 Recent data indicate that Bax can neutralize the actions of Bcl-2 by forming heterodimers with Bcl-2. 7 Moreover, homodimers of Bax may independently trigger apoptotic signaling further downstream. 8 Apoptosis of cardiomyocytes occurs in animal models of cardiomyopathy and human heart failure, and the development of cardiomyopathy and myocardial remodeling may involve increased apoptosis of cardiomyocytes. 9 Although apoptosis in cardiac muscle has just now been recognized, how it occurs is not yet clear, and further investigation into its molecular mechanisms is required. IGF I may improve cardiac function in animal models of cardiomyopathy, 1,2,10 -13 but the actions of IGF I on apoptotic pathways in cardiac muscle cells are largely unknown. To this end, we have studied the effects of IGF I on Bcl-2, Bax, caspase 3, and DNA fragmentation in primary cardiomyocytes isolated from fetal rats.
Materials and Methods

Materials
FBS and cell culture medium were purchased from Irvine Scientific. Terminal deoxynucleotidyl transferase was from Pharmacia. Polyvinylidene fluoride membranes and reagents for SDS-PAGE were purchased from Bio-Rad Laboratories. Protein concentrations were analyzed with the Bio-Rad protein assay kit. Anti-Bcl-2 and antiBax antibodies were from Santa Cruz Biotechnology or Oncogene Research Products. Recombinant GST-Bcl-2 and GST-Bax fusion proteins were from Santa Cruz Biotechnology. IGF-I was supplied by Genentech. [␣-32 P]ATP was from Amersham. Other chemicals were purchased from Sigma Chemical Co or Fisher. rats as previously described.
14 After disaggregation with 0.125% pancreatin, nonmuscle cells were minimized by differential plating. 15 At the time of experiments, these preparations contained Ͻ10% fibroblasts. Myocytes were cultured at a density of 8ϫ10 6 cells per T-75 flask overnight in 10 mL DMEM containing 10% FBS. The cells were trypsinized and plated (Ϸ25 000 to 30 000 cells/cm 2 ) in 8-well slides for in situ DNA fragmentation studies and in 100-mm dishes for other studies. All experiments in the present study used 60% to 70% confluent cells. In experiments with IGF I, primary cardiomyocytes were rinsed 3 times with 0.5% BSAϩDMEM, serum-starved for 18 hours in 0.5% BSAϩDMEM, rinsed 3 times with 0.5% BSAϩDMEM, and then incubated with IGF I at the indicated concentrations. To induce apoptosis, the cells were rinsed 3 times with DMEM and then serum-deprived (DMEMϩ0.5% BSA) in the presence or absence of the indicated concentrations of doxorubicin for 14 to 15 hours. To study the effects of IGF I on apoptotic signaling, IGF I was added to the culture medium 20 minutes before the addition of doxorubicin for all experiments involving IGF I.
MTT Assay
Cell viability was analyzed by MTT assay as previously described. 16 For this assay, equal numbers of contractile cardiomyocytes were plated on 96-well plates (Ϸ30 000 cells/well) and maintained in regular growth medium for 2 days. The cells then underwent doxorubicin and IGF I treatment when indicated, as described earlier.
MTT reagents (final concentration, 0.625 mg/mL) were added to each well and incubated at 37°C for 4 hours, and the cells were lysed with acidic isopropanol (0.04N HCl). After incubation at room temperature for 15 minutes, the plates were then analyzed with a multiwell ELISA reader at 570 and 650 nmol/L.
DNA Fragmentation
The attached cells were scraped and, together with the detached cells floating in the medium, were collected by centrifugation at 2000g for 10 minutes. The pellets were lysed with a lysis buffer (20 mmol/L EDTA, 50 mmol/L Tris-HCl [pH 8.0], 0.5% SDS, and 100 g/mL proteinase K) and incubated at 37°C for 5 hours. 17 Nucleic acids were treated with RNase A (100 g/mL), and DNA was extracted by the phenol/chloroform method and precipitated with 60% (vol/vol) isopropanol. Two micrograms of DNA was labeled with terminal deoxynucleotidyl transferase (tdt) for 90 minutes at 37°C. 18 The unincorporated nucleotides were removed, and the labeled DNA was resolved with 8% acrylamide gel. The gels were dried and exposed for autoradiography. To quantify fragmentation of DNA, the radioactivity by autoradiography from 100 bp to 1 kb was determined by laser densitometry.
In Situ TUNEL Assay
In situ labeling of fragmented DNA was performed with tdt UTP nick end-labeling (TUNEL). 19 Monolayers of cardiomyocytes were grown on slides and fixed with 4% buffered formalin. TUNEL assay was performed with the commercially available ApopTag Plus kit (Oncor) according to the manufacturer's instructions. In brief, nucleosome-sized DNA fragments were tailed with digoxigenin-nucleotide and then reacted with fluorescein-conjugated antidigoxigenin antibodies. The nucleus was counterstained with DAPI. 20 The apoptotic and nonapoptotic nuclei were visualized with a Bio-Rad laser scanning confocal fluorescence microscope equipped with the MRC 1024 UV system. The image was recorded with LaserSharp software, and the photographs were printed with a Codonic NP-1600 printer.
Immunoblotting and Immunoprecipitation
Cell monolayers were incubated with defined medium in the presence or absence of doxorubicin and IGF I. The cells were then rinsed once with 1ϫ PBS and solubilized with a buffer containing 50 mmol/L Tris (pH 7.4), 100 mmol/L sodium chloride, 10 g/mL aprotinin, 5 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 10 g/mL leupeptin, and 1% Triton X-100 on ice. The homogenates were centrifuged at 10 000g for 10 minutes. Protein concentrations in the supernatants were determined by the Bradford method, 21 and equal amounts of supernatants (20 to 400 g protein/ lane) were separated by 12% SDS-PAGE. The resolved proteins were electronically transferred to polyvinylidene fluoride filters in a transfer buffer (192 mmol/L glycine, 15% methanol [vol/vol], and 25 mmol/L Tris-HCl). To reduce nonspecific binding, the filters were incubated in a blocking buffer (20 mmol/L Tris [pH 7.6], 137 mmol/L NaCl, 5% nonfat milk, and 0.05% Tween 20) at 25°C for 1 hour. The filters were incubated with anti-Bcl-2 or anti-Bax antibodies overnight at 4°C and washed with washing buffer (1ϫ TBS [pH 7.6] and 0.05% Tween 20) 6 times for 5 minutes each. The results of immunoblotting were visualized with enhanced chemiluminescence. 22 In selective experiments, immunoprecipitation was carried out by incubating cell lysates with agarose-conjugated antiBcl-2 antibodies overnight at 4°C. The agarose beads were collected by brief centrifugation and washed 4 times. The protein complexes were then eluted from the beads and applied to SDS-PAGE for subsequent immunoblotting with anti-Bax antibodies.
Caspase 3 Activities
The activities of caspase 3 were determined with the CPP32 assay kit (Clontech) by the detection of chromophore p-nitroanilide after cleavage from the labeled substrate Asp-Glu-Val-Asp (DEVD)-pnitroanilide as previously described. 5 In brief, 2ϫ10 6 cells were solubilized, and equal amounts of protein lysates were reacted with 50 mol/L DEVD-p-nitroanilide at 37°C for 1 hour. The activity was read in a spectrophotometer at 405 nmol/L, and the results were calibrated with known concentrations of p-nitroanilide. The units of protease activity were defined as the amount of caspase 3 required to produce 1 pmol of p-nitroanilide at 25°C.
Nucleosome ELISA
The quantities of mononucleosomes and oligonucleosomes generated in the apoptotic cardiomyocytes were determined with a quantitative nucleosome ELISA by affinity capturing of free nucleosomes with precoated DNA binding proteins. Anti-histone 3 biotinlabeled antibodies were used to detect the levels of nucleosomes with a microplate ELISA reader. This assay was carried out with a commercially available kit from Calbiochem.
Statistical Analysis
All autoradiogram were analyzed by laser densitometry. The data were presented as meanϮSE, and the statistical significance was tested by the Student t test.
Results
IGF I Suppressed Apoptosis of Cardiomyocytes and Enhanced Cell Survival
DNA Fragmentation and Cell Survival
The purpose of this series of experiments was to determine whether we could induce apoptosis in vitro in cultured primary cardiomyocytes and to assess whether IGF I might suppress the apoptosis of cultured cardiomyocytes. Serum withdrawal has been shown to induce apoptosis in cells. To assess whether serum withdrawal may induce apoptosis in cardiomyocytes, we performed pilot studies and found that overnight serum withdrawal causes DNA fragmentation. However, fragmentation of DNA under serum withdrawal was not as dramatic as previously reported in other types of cells. Since doxorubicin has been shown to induce apoptosis in other cells and doxorubicin may cause cardiomyopathy in humans, we added doxorubicin to the cells incubated with serum-free medium and found that DNA fragmentation was significantly increased. As shown in Figure 1 , moderate DNA fragmentation was found in the cells grown overnight in serum-free medium, and the addition of doxorubicin further increased DNA fragmentation in these cells. To test whether IGF I can suppress apoptosis of cardiomyocytes, the cells were incubated with serum-free medium containing IGF I for 20 minutes before the addition of doxorubicin. IGF I partially suppressed the DNA fragmentation induced by serum withdrawal and doxorubicin, indicating that apoptosis of cardiomyocytes can be attenuated with IGF I treatment. In parallel with these studies, the viability of the cells was analyzed with MTT assay as shown in Figure 2 . The cells underwent serum withdrawal, doxorubicin, and/or IGF I treatment as described above. Serum withdrawal overnight induced 23% reduction in MTT activities, and the addition of doxorubicin further reduced MTT activities to 53% of the control cells. Consistent with the effects of IGF I on DNA fragmentation, IGF I partially enhanced the viability of cardiomyocytes in the presence of serum-free medium and doxorubicin.
In Situ TUNEL Assay
To assess the occurrence of apoptosis in situ, broken DNA in the nucleus was labeled with TUNEL assay and visualized by fluorescence microscopy. Figure 3 shows photomicrographs of a typical TUNEL assay; the apoptotic nuclei were stained green. All nuclei, apoptotic and nonapoptotic, were counterstained with DAPI, which appeared blue. Compared with the control cells, more apoptotic nuclei were identified in the cells grown in serum-free medium and doxorubicin ( Figure  4) . The results of multiple TUNEL assays show that serum withdrawal increased the number of apoptotic nuclei by 6-fold and that the addition of doxorubicin further increased apoptotic nuclei by 13-fold. IGF I treatment significantly decreased the number of apoptotic nuclei after serum withdrawal and doxorubicin incubation. These data are consistent with the results of DNA fragmentation experiments described above and confirm that apoptosis of cardiomyocytes can be induced with serum withdrawal and doxorubicin and that IGF I can attenuate the apoptosis of cardiomyocytes induced by serum withdrawal and doxorubicin.
IGF I Regulated the Contents of Bax Protein and Modulated Bcl-2-Bax Interactions
The execution of apoptosis is mediated by specific apoptotic signaling molecules. To understand how serum withdrawal and doxorubicin induced apoptosis and how IGF I attenuated cardiomyocyte apoptosis, we have determined the abundance of Bcl-2 and Bax by immunoblot analysis ( Figure 5 ). The levels of Bcl-2 were low in these cells. Although Bcl-2 protein can be easily detected in cardiac fibroblasts, the band representing Bcl-2 was very faint in cardiomyocytes, and in many experiments we were not able to detect a clear Bcl-2 band with the use of 3 different anti-Bcl-2 antibodies that react with rat Bcl-2. In contrast, Bax protein can be readily detected with antibodies that interact with rat Bax. Bax was induced by serum withdrawal and doxorubicin and partially attenuated by IGF I. In contrast, the abundance of tubulin was not significantly altered by serum withdrawal, doxorubicin, or IGF I. Bax protein was visualized by the enhanced chemiluminescence technique after Ͻ20 seconds of exposure. However, we had to load abundant cell lysates (100 to 400 g protein/lane) on SDS-PAGE and expose the autoradiograph for a considerable period of time (15 to 30 minutes) to visualize a faint band, if there is any, of Bcl-2. To more accurately compare the abundance of Bax and Bcl-2 proteins, their levels were compared with known dilutions of recombinant GST-Bcl-2 and GST-Bax fusion proteins ( Figure 6 ). The results shows that Bax levels were much higher than Bcl-2 levels in these cells.
Compared with the control condition, the abundance of Bax was increased by 80% after serum deprivation and by 3-fold after the addition of doxorubicin (Figure 7) , suggesting that Bax is involved in the apoptotic signaling induced by serum withdrawal and doxorubicin treatment. When cardiomyocytes were pretreated with IGF I before serum withdrawal and incubation with doxorubicin, induction of Bax protein was reduced. Since increased Bax expression is associated with increased apoptosis, these results suggest that IGF I may attenuate the apoptotic effects of serum withdrawal and doxorubicin partly by inhibiting Bax induction.
Increased expression of Bax may lead to the formation of Bax-Bcl-2 heterodimers. To determine whether serum withdrawal and doxorubicin result in increased formation of Bax-Bcl-2 complexes, cell lysates were first immunoprecipitated with anti-Bcl-2 antibodies and then immunoblotted with anti-Bax antibodies (Figure 8 ). Since the level of Bcl-2 protein is quite low in these cells, considerably large amount of cell lysates (1 mg protein/sample) were used for this experiment. The results show that Bcl-2-associated Bax was significantly increased after serum withdrawal and doxorubicin treatment and that IGF I treatment reduced the abundance of Bcl-2-associated Bax in cardiomyocytes. Thus, serum withdrawal and doxorubicin lead to increased formation of Bcl-2-Bax complexes, and IGF I reduces Bcl-2-Bax formation. 
IGF I Attenuated Activation of Caspase 3 by Serum Withdrawal and Doxorubicin
Increased abundance of Bax and formation of Bcl-2-Bax heterodimers may result in activation of caspase 3, an important component of the final pathway leading to the occurrence of cell death. To this end, the activities of caspase 3 were determined, and the results are shown in Figure 9 . Compared with caspase 3 activity in the control condition, caspase 3 activities increased by 80% 14 hours after serum withdrawal and by 4.5-fold when 0.5 mol/L doxorubicin was added. In parallel to its effects on DNA fragmentation and Bax, IGF I partially inhibited the activation of caspase 3 by Ϸ43%. In cardiomyocytes treated with serum-free medium and doxorubicin, the addition of a specific caspase 3 inhibitor, DEVD-CHO, in vivo to the medium or in vitro to the reaction buffer suppressed the activities of caspase 3 to the control level, indicating that the activities of caspase 3 that we measured were quite specific. These data show that apoptosis of cardiomyocytes may involve caspase 3 and that the antiapoptotic action of IGF I on cardiomyocytes can be partially explained by the inhibition of caspase 3 activation.
Dose-Response Effects of IGF I on Apoptotic Signaling
The dose-response effects of IGF I on apoptotic signaling were defined with nucleosome ELISA and caspase 3 activation (Table) . The generation of nucleosomal DNA represents a hallmark of apoptosis; nucleosome ELISA allowed us to acutely quantify the presence of mononucleosomes and oligonucleosomes. The results show that half-maximal effects of IGF I occurred below 10 Ϫ9 mol/L in primary cardiomyocytes. These data indicate that antiapoptotic actions can occur at physiological plasma concentrations of IGF I, suggesting that endogenous IGF I may exert its antiapoptotic effects on cardiac muscle in vivo. 
Discussion
Cardiomyocytes are highly differentiated cells and rarely replicate after birth. In adult mammals, loss of cardiomyocytes will result in a permanent reduction of the number of functioning units in the myocardium. For decades it has been assumed that cardiomyocytes die only by necrosis, such as in the case of reduced oxygen supply. However, with improved assays and technology, recent studies show that another form of cell death, apoptosis, also occurs in cardiomyocytes and contributes to the development of heart failure. [23] [24] [25] Necrosis of the myocardium rarely occurs in nonischemic forms of cardiomyopathy. 26 Instead, patchy loss of cardiomyocytes through apoptosis contributes to the progressive deterioration of myocardial function. This emerging concept of cardiomyocyte apoptosis has important implications regarding myocardial function, because loss of cardiomyocytes could be a fundamental part of the myocardial process that initiates or aggravates heart failure in cardiomyopathy. 26 The in vitro antiapoptotic effect of IGF I on cardiomyocytes that we have observed is consistent with the results of recent in vivo studies. In a murine model of myocardial ischemia/reperfusion, IGF I administration resulted in a decreased incidence of myocardial apoptosis. 1 When the coronary artery was ligated to create an experimental myocardial infarction in mice, transgenic mice overexpressing IGF I in myocardium showed decreased cell death and less ventricular dilatation and wall stress.
2 IGF I is capable of augmenting cardiac function in experimental cardiomyopathy. 10 -13 Although the contribution of its antiapoptotic actions to the overall effects of IGF I on the heart still awaits to be determined, IGF I may conceivably attenuate the loss of functioning myocardial units by suppressing apoptosis in cardiomyocytes.
Apoptotic signaling pathways in cardiomyocytes remain largely unknown. We have begun to study apoptotic signaling pathways in primary cardiomyocytes. These cells were harvested from near-term fetuses and became nonproliferating contractile cardiomyocytes several days after isolation. The content of antiapoptotic Bcl-2 protein is much lower than proapoptotic Bax in fetal cardiomyocytes. Thus, the ratio of Bcl-2 to Bax is quite low in primary cardiomyocytes. After the induction of apoptosis with serum withdrawal and doxorubicin, the levels of Bax protein increased, and the formation of Bax-Bcl-2 complexes also increased. These changes may play a role in the subsequent activation of caspase 3 and the progress of apoptosis. It is believed that once the caspase cascades are activated, the cell death process cannot be reversed.
Exactly how caspases are activated is not yet clear, but it appears that the Bcl-2 gene family is involved in this process.
The formation of homodimers and heterodimers between the antiapoptotic family members and the proapoptotic family members has been shown to provide a potential mechanism of apoptosis execution. 5 Homodimers of Bcl-2 associate with mitochondrial membrane, stabilize membrane permeability, and prevent the efflux of cytochrome C and the subsequent activation of caspase 3. 4 The stabilizing effect of Bcl-2 on mitochondria permeability disappears when Bcl-2 homodimers are sequestered by the formation of the Bcl-2-Bax heterodimer. 3, 4 Furthermore, Bax homodimers can be associated with mitochondria and directly activate caspase 3 and other potential cell death pathways. 4 How IGF I regulates apoptotic signaling is not well understood, but our study suggesting that the inhibitory actions of IGF I on caspase 3 activation may represent a critical step through which IGF I modulates apoptotic signaling in cardiomyocytes. The effects of IGF I on the Bcl-2 family were not the same in different types of cells. IGF I restored the contents of Bcl-2 and/or Bcl-xL in myeloid cells and PC-12 cells. 27, 28 But the expression of Bax was not modulated by IGF I in myeloid cells. 28 In neuronal cells, activation of the IGF I receptor is accompanied by the induction of Bcl-2 and Bcl-xL and the suppression of caspase 3. 29 However, IGF I inhibits the activation of interleukin-1␤-converting enzyme without changing the expression of Bcl-2, Bcl-x, or Bax in COS cells. 30 Although differential IGF I regulation of the Bcl-2 family may be in part due to different apoptosis inducers, these studies and our results show that IGF I usually suppresses caspases regardless of the changes in the Bcl-2 family. Cardiomyopathy resulting from right ventricular hyperplasia is associated with increased expression of caspase 3 in the myocardium. 31 These patients have progressive loss of cardiomyocytes from their myocardium; thus, suppression of caspase 3 may offer a potential target of therapeutic manipulation to prevent cardiomyocyte loss in cardiomyopathy.
Clinical use of doxorubicin is associated with increased risk of heart failure. 32 Although the molecular mechanisms underlying doxorubicin cardiomyopathy are not yet fully understood, the formation of free radicals was increased when myocardium was exposed to doxorubicin in vivo. 33 Since free radical formation may induce the occurrence of apoptosis, 34 it is possible that doxorubicin-induced cardiomyopathy may involve apoptosis in cardiomyocytes. To test the effects of IGF I in the present study, apoptosis was induced under serum-free conditions. Apoptosis in cardiomyocytes also occurred when doxorubicin was added to the regular growth medium that contained 10% serum. However, higher doses of doxorubicin used in subsequent studies (2 to 4 times higher than the dose used for the present study) were required to produce comparable cytotoxic effects (authors' unpublished data, 1998). This is probably because growth factors in serum, including IGF I, provided protective effects against apoptotic induction.
In summary, apoptosis of cardiomyocytes is an intriguing paradigm that may have significant physiological and pathophysiological implications regarding normal and diseased myocardium. We have shown that in primary cardiomyocytes, apoptosis induced by serum withdrawal and doxorubicin is associated with the induction of Bax and activation of caspase 3. IGF I treatment resulted in attenuated Bax induction and caspase 3 activation and inhibited DNA fragmentation. The formation of Bcl-2-Bax complexes was also increased after the induction of apoptosis and was reduced after IGF I treatment. These data suggest that Bax and caspase 3 are key elements of the signaling pathway through which IGF I inhibits the induction of apoptosis in cardiomyocytes. Our findings may provide new insight into how doxorubicin and IGF I modulate myocardial structure and function.
